Biomedical Advanced Research and Development Authority (BARDA) Exercises Contract Option as Emergent BioSolutions Achieves Significant Progress in rPA Anthrax

Published: Oct 05, 2012

ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions (NYSE:EBS) announced today that, after completion of an inter-agency In Process Review, the Biomedical Advanced Research Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) has exercised a contract option to further advance the development of PreviThraxTM (Recombinant Protective Antigen Anthrax Vaccine, Purified), the company’s novel rPA anthrax vaccine candidate. This option is part of the company’s rPA development contract with BARDA executed in October 2010.

Back to news